Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 May;17(3):204-7.
doi: 10.1007/s00192-005-1370-x. Epub 2005 Jul 28.

Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up

Bariş Nuhoğlu  1 , Vecihi Fidan, Ali Ayyildiz, Erim Ersoy, Cankon Germiyanoğlu
Affiliations

Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up

Bariş Nuhoğlu et al. Int Urogynecol J Pelvic Floor Dysfunct. 2006 May.

Abstract

Aim: In this prospective observational study, we investigated the efficacy of Stoller afferent nerve stimulation (SANS) in subjects with overactive bladder who failed anticholinergic treatment.

Methods: Thirty-five subjects with overactive bladder who failed therapy with oxybutynin participated in this study. Treatment (n = 35) was given once a week for 30 minutes for overall 10 weeks. In treatment, SANS device (Urosurge) was used. Subjects were assessed with 3-day voiding diary, SEAPI quality of life questionnaires and cystometry before therapy after completion of therapy and at one-year follow-up.

Results: In 54% (n = 19) of subjects complete recovery was obtained after treatment. Urgency and SEAPI were reduced significantly whereas urine volume increased significantly (p < 0.01). Complete recovery was maintained in eight of the 19 subjects at one year.

Conclusions: SANS treatment has a short-term positive effect in patients with resistant overactive bladder. However, it was also established that efficacy was maintained at 1 year in only 23% of subjects.

PubMed Disclaimer

References

    1. Drugs. 2004;64(15):1643-56 - PubMed
    1. Neurourol Urodyn. 2002;21(2):167-78 - PubMed
    1. J Urol. 2001 Apr;165(4):1193-8 - PubMed
    1. Urology. 2004 Mar;63(3 Suppl 1):32-41 - PubMed
    1. J Urol. 2001 Jan;165(1):169-73 - PubMed

MeSH terms

LinkOut - more resources